Company Profile
Allogene Therapeutics Stock Price, News & Analysis
Company overview
Business overview
Allogene Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Allogene Therapeutics is followed within the biopharmaceutical universe for its exposure to pipeline and commercialization catalysts.
Business Model Characteristics
Allogene Therapeutics follows a pipeline-led model where clinical readouts, filing updates, and program expansion determine how the market underwrites the story.
Position Within the Biotechnology Landscape
Compared with more mature healthcare names, Allogene Therapeutics sits on the development side of the biotech landscape, where catalyst timing can reprice the stock quickly.
Why the stock is moving
ALLO is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Future catalysts
Allogene's next chapter is built around Cema-Cel and the ALPHA3 trial. The MRD-guided consolidation setting gives the company a very specific commercial and clinical angle, and that precision is useful because it makes the next set of updates much easier to judge.
Recent news
The five most recent feed items are shown below in reverse chronological order.
- 01
Allogene Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update
Source: Allogene Therapeutics
- 02
- 03
- 04
Allogene Therapeutics Announces Proposed Public Offering of $175 Million of Common Stock
Source: Allogene Therapeutics
- 05
Allogene Therapeutics Announces Pricing of Public Offering of Common Stock
Source: Allogene Therapeutics
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.